Intelligence / Healthtech / New Clinical Trials / GuangZhou Cellgenes Biotechnology Co., Ltd.
GuangZhou Cellgenes Biotechnology Co., Ltd.
27 Oct 2026: Trial registered · Safety and Efficacy of CG-BM1 in Ischemic Stroke. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 27 Oct 2026
- Title
- Safety and Efficacy of CG-BM1 in Ischemic Stroke
- Conditions
- Ischemic Stroke or High-risk TIA (ABCD² ≥ 4)
- Phase
- Phase 1, Phase 2
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07896941
- Location
- China
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at GuangZhou Cellgenes Biotechnology Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for GuangZhou Cellgenes Biotechnology Co., Ltd. in our registers.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.